These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 32259540

  • 1. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy.
    Sánchez Acosta G, Kinaciyan T, Kitzmüller C, Möbs C, Pfützner W, Bohle B.
    J Allergy Clin Immunol; 2020 Oct; 146(4):894-900.e2. PubMed ID: 32259540
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
    Kinaciyan T, Nagl B, Faustmann S, Frommlet F, Kopp S, Wolkersdorfer M, Wöhrl S, Bastl K, Huber H, Berger U, Bohle B.
    J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
    [Abstract] [Full Text] [Related]

  • 3. IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1.
    Grilo JR, Kitzmüller C, Aglas L, Sánchez Acosta G, Vollmann U, Ebner C, Horak F, Kinaciyan T, Radauer C, Ferreira F, Jahn-Schmid B, Bohle B.
    Allergy; 2021 Aug; 76(8):2555-2564. PubMed ID: 33724487
    [Abstract] [Full Text] [Related]

  • 4. The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy.
    van der Valk JPM, Nagl B, van Wljk RG, Bohle B, de Jong NW.
    Nutrients; 2020 Feb 18; 12(2):. PubMed ID: 32085633
    [Abstract] [Full Text] [Related]

  • 5. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B, Schiller D, Möbs C, de Jong NW, Ebner C, Reider N, Bartel D, Lidholm J, Pfützner W, Gerth van Wijk R, Vieths S, Bohle B.
    Allergy; 2013 Nov 18; 68(11):1377-86. PubMed ID: 24053565
    [Abstract] [Full Text] [Related]

  • 6. Cross-protection of AIT-induced antibodies to related allergens requires a high degree of structural identity.
    Demir H, Radauer C, Strobl MR, Scheurer S, Kinaciyan T, Bohle B.
    Allergy; 2024 Sep 23. PubMed ID: 39311416
    [Abstract] [Full Text] [Related]

  • 7. IgE, IgG4 and IgA specific to Bet v 1-related food allergens do not predict oral allergy syndrome.
    Guhsl EE, Hofstetter G, Lengger N, Hemmer W, Ebner C, Fröschl R, Bublin M, Lupinek C, Breiteneder H, Radauer C.
    Allergy; 2015 Jan 23; 70(1):59-66. PubMed ID: 25327982
    [Abstract] [Full Text] [Related]

  • 8. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M, Kinaciyan T, Nagl B, Baumgartner-Durchschlag U, Huber H, Ebner C, Lidholm J, Bartel D, Vieths S, Jahn-Schmid B, Bohle B.
    J Allergy Clin Immunol; 2013 Jan 23; 131(1):94-102. PubMed ID: 22921871
    [Abstract] [Full Text] [Related]

  • 9. Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollen-allergic patients with apple allergy.
    Kinaciyan T, Nagl B, Faustmann S, Kopp S, Wolkersdorfer M, Bohle B.
    Allergy; 2016 Feb 23; 71(2):272-4. PubMed ID: 26443126
    [Abstract] [Full Text] [Related]

  • 10. In vivo Induction of Functional Inhibitory IgG Antibodies by a Hypoallergenic Bet v 1 Variant.
    Aglas L, Bethanis A, Chrusciel P, Stolz F, Gruen M, Jaakkola UM, Jongejan L, Yatkin E, Van Ree R.
    Front Immunol; 2020 Feb 23; 11():2118. PubMed ID: 33013894
    [Abstract] [Full Text] [Related]

  • 11. Natural human Bet v 1-specific IgG antibodies recognize non-conformational epitopes whereas IgE reacts with conformational epitopes.
    Brazhnikov G, Smolnikov E, Litovkina A, Jiang T, Shatilov A, Tulaeva I, Tulaev M, Karaulov A, Poroshina A, Zhernov Y, Focke-Tejkl M, Weber M, Akinfenwa O, Elisyutina O, Andreev S, Shilovskiy I, Shershakova N, Smirnov V, Fedenko E, Lepeshkova TS, Beltyukov EC, Naumova VV, Kundi M, Khaitov M, Wiedermann U, Valenta R, Campana R.
    Allergy; 2023 Dec 23; 78(12):3136-3153. PubMed ID: 37701941
    [Abstract] [Full Text] [Related]

  • 12. Pollen-related food allergy: cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen.
    Son DY, Scheurer S, Hoffmann A, Haustein D, Vieths S.
    Eur J Nutr; 1999 Aug 23; 38(4):201-15. PubMed ID: 10502033
    [Abstract] [Full Text] [Related]

  • 13. Effect of Lactobacillus rhamnosus GG on rBet v1 and rMal d1 specific IgA in the saliva of patients with birch pollen allergy.
    Piirainen L, Haahtela S, Helin T, Korpela R, Haahtela T, Vaarala O.
    Ann Allergy Asthma Immunol; 2008 Apr 23; 100(4):338-42. PubMed ID: 18450119
    [Abstract] [Full Text] [Related]

  • 14. Clinical benefit of component-resolved diagnosis in Japanese birch-allergic patients with a convincing history of apple or peach allergy.
    Shirasaki H, Yamamoto T, Abe S, Kanaizumi E, Kikuchi M, Himi T.
    Auris Nasus Larynx; 2017 Aug 23; 44(4):442-446. PubMed ID: 27816237
    [Abstract] [Full Text] [Related]

  • 15. Birch pollen immunotherapy inhibits anaphylaxis to the cross-reactive apple allergen Mal d 1 in mice.
    Utsch L, Logiantara A, Wallner M, Hofer H, van Ree R, van Rijt LS.
    Clin Exp Allergy; 2016 Nov 23; 46(11):1474-1483. PubMed ID: 27376790
    [Abstract] [Full Text] [Related]

  • 16. High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China.
    Hao GD, Zheng YW, Wang ZX, Kong XA, Song ZJ, Lai XX, Spangfort MD.
    J Zhejiang Univ Sci B; 2016 May 23; 17(5):399-404. PubMed ID: 27143268
    [Abstract] [Full Text] [Related]

  • 17. Sensitization profiles in birch pollen-allergic patients with and without oral allergy syndrome to apple: lessons from multiplexed component-resolved allergy diagnosis.
    Ebo DG, Bridts CH, Verweij MM, De Knop KJ, Hagendorens MM, De Clerck LS, Stevens WJ.
    Clin Exp Allergy; 2010 Feb 23; 40(2):339-47. PubMed ID: 19709127
    [Abstract] [Full Text] [Related]

  • 18. Two different profiles of peach allergy in the north of Spain.
    Gamboa PM, Cáceres O, Antepara I, Sánchez-Monge R, Ahrazem O, Salcedo G, Barber D, Lombardero M, Sanz ML.
    Allergy; 2007 Apr 23; 62(4):408-14. PubMed ID: 17362252
    [Abstract] [Full Text] [Related]

  • 19. Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells.
    Fritsch R, Bohle B, Vollmann U, Wiedermann U, Jahn-Schmid B, Krebitz M, Breiteneder H, Kraft D, Ebner C.
    J Allergy Clin Immunol; 1998 Oct 23; 102(4 Pt 1):679-86. PubMed ID: 9802379
    [Abstract] [Full Text] [Related]

  • 20. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy.
    Khaitov M, Shilovskiy I, Valenta R, Weber M, Korneev A, Tulaeva I, Gattinger P, van Hage M, Hofer G, Konradsen JR, Keller W, Akinfenwa O, Poroshina A, Ilina N, Fedenko E, Elisyutina O, Litovkina A, Smolnikov E, Nikonova A, Rybalkin S, Aldobaev V, Smirnov V, Shershakova N, Petukhova O, Kudlay D, Shatilov A, Timofeeva A, Campana R, Udin S, Skvortsova V.
    Allergy; 2024 Apr 23; 79(4):1001-1017. PubMed ID: 37855043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.